Cargando…
Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study
BACKGROUND: Syndecan-1 is a heparan sulfate proteoglycan expressed on plasma cells, especially myeloma cells, and can exist in serum as soluble syndecan-1 after shedding from the cell surface. Soluble syndecan-1 has been suggested to promote myeloma cell growth and to be an independent prognostic fa...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983025/ https://www.ncbi.nlm.nih.gov/pubmed/21120190 http://dx.doi.org/10.5045/kjh.2010.45.2.115 |
_version_ | 1782191789745111040 |
---|---|
author | Kim, Ji Myung Lee, Jung Ae Cho, In Sung Ihm, Chun Hwa |
author_facet | Kim, Ji Myung Lee, Jung Ae Cho, In Sung Ihm, Chun Hwa |
author_sort | Kim, Ji Myung |
collection | PubMed |
description | BACKGROUND: Syndecan-1 is a heparan sulfate proteoglycan expressed on plasma cells, especially myeloma cells, and can exist in serum as soluble syndecan-1 after shedding from the cell surface. Soluble syndecan-1 has been suggested to promote myeloma cell growth and to be an independent prognostic factor for multiple myeloma. We aimed to evaluate the effect of soluble syndecan-1 levels at the time of diagnosis and during therapy on therapeutic response and prognosis for patients with multiple myeloma. METHODS: We analyzed soluble syndecan-1 levels in 28 patients with multiple myeloma and 50 normal controls, and compared its levels with Durie-Salmon stage and other markers of myeloma. In addition, we evaluated the therapeutic response and determined the 3-year survival rates of these patients. RESULTS: We observed that the median soluble syndecan-1 level in myeloma patients was higher than that in the normal controls (P <0.0001), and the soluble syndecan-1 levels in 21 (75%) patients were higher than the cut-off level (162 ng/mL). Soluble syndecan-1 levels correlated with disease stage, percentage of plasma cells in the bone marrow, β(2) microglobulin level, serum M-component concentration, and creatinine level. The baseline levels of soluble syndecan-1 at the time of diagnosis in the patients who responded to chemotherapy were lower than those in the non-responders (P=0.04); however, the baseline level was not a significant predictor of therapeutic response. The 3-year overall survival rate of the patients with high soluble syndecan-1 levels at the time of diagnosis and 6 months after chemotherapy was lower than the corresponding survival rates of the patients with low levels of soluble syndecan-1; however, the overall survival rate was not statistically significant. CONCLUSION: The use of soluble syndecan-1 has limitations in the diagnosis of multiple myeloma. Soluble syndecan-1 levels correlate with known prognostic factors; however, we could not assess the prognostic value of high levels of soluble syndecan-1 at the time of diagnosis and after chemotherapy. |
format | Text |
id | pubmed-2983025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-29830252010-11-30 Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study Kim, Ji Myung Lee, Jung Ae Cho, In Sung Ihm, Chun Hwa Korean J Hematol Original Article BACKGROUND: Syndecan-1 is a heparan sulfate proteoglycan expressed on plasma cells, especially myeloma cells, and can exist in serum as soluble syndecan-1 after shedding from the cell surface. Soluble syndecan-1 has been suggested to promote myeloma cell growth and to be an independent prognostic factor for multiple myeloma. We aimed to evaluate the effect of soluble syndecan-1 levels at the time of diagnosis and during therapy on therapeutic response and prognosis for patients with multiple myeloma. METHODS: We analyzed soluble syndecan-1 levels in 28 patients with multiple myeloma and 50 normal controls, and compared its levels with Durie-Salmon stage and other markers of myeloma. In addition, we evaluated the therapeutic response and determined the 3-year survival rates of these patients. RESULTS: We observed that the median soluble syndecan-1 level in myeloma patients was higher than that in the normal controls (P <0.0001), and the soluble syndecan-1 levels in 21 (75%) patients were higher than the cut-off level (162 ng/mL). Soluble syndecan-1 levels correlated with disease stage, percentage of plasma cells in the bone marrow, β(2) microglobulin level, serum M-component concentration, and creatinine level. The baseline levels of soluble syndecan-1 at the time of diagnosis in the patients who responded to chemotherapy were lower than those in the non-responders (P=0.04); however, the baseline level was not a significant predictor of therapeutic response. The 3-year overall survival rate of the patients with high soluble syndecan-1 levels at the time of diagnosis and 6 months after chemotherapy was lower than the corresponding survival rates of the patients with low levels of soluble syndecan-1; however, the overall survival rate was not statistically significant. CONCLUSION: The use of soluble syndecan-1 has limitations in the diagnosis of multiple myeloma. Soluble syndecan-1 levels correlate with known prognostic factors; however, we could not assess the prognostic value of high levels of soluble syndecan-1 at the time of diagnosis and after chemotherapy. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010-06 2010-06-30 /pmc/articles/PMC2983025/ /pubmed/21120190 http://dx.doi.org/10.5045/kjh.2010.45.2.115 Text en © 2010 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Ji Myung Lee, Jung Ae Cho, In Sung Ihm, Chun Hwa Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title_full | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title_fullStr | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title_full_unstemmed | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title_short | Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
title_sort | soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983025/ https://www.ncbi.nlm.nih.gov/pubmed/21120190 http://dx.doi.org/10.5045/kjh.2010.45.2.115 |
work_keys_str_mv | AT kimjimyung solublesyndecan1atdiagnosisandduringfollowupofmultiplemyelomaasingleinstitutionstudy AT leejungae solublesyndecan1atdiagnosisandduringfollowupofmultiplemyelomaasingleinstitutionstudy AT choinsung solublesyndecan1atdiagnosisandduringfollowupofmultiplemyelomaasingleinstitutionstudy AT ihmchunhwa solublesyndecan1atdiagnosisandduringfollowupofmultiplemyelomaasingleinstitutionstudy |